The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML ---- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and ...
Forty Seven has raised $75 million, bringing its total haul to date up to $150 million. The series B round equips the Stanford University spinout to expand trials of its CD47-targeted approach to ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Just before Christmas and, critically, after announcing some positive data, Forty Seven sat down at Gilead Sciences' HQ with its C-suite to talk M&A. Gilead liked what it saw, according to a recent ...
MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, ...
(Reuters) - Gilead Sciences Inc said on Monday it would buy Forty Seven Inc for $4.9 billion in cash, adding an experimental treatment that targets blood cancer to its portfolio of oncology drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results